Effect of an L-carnitine-containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)
Phase 2 Study of the Effect of a Peritoneal Dialysis Solution Containing Glucose (1.5%) and L-carnitine (0.1%) on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis
Sponsor: Iperboreal Pharma Srl
Listed as NCT00755456, this PHASE2 trial focuses on End Stage Renal Disease and Insulin Resistance and remains completed. Sponsored by Iperboreal Pharma Srl, it has been updated 8 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Unknown Status PHASE2
-
May 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — May 2017 [monthly]
Unknown Status PHASE2
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Iperboreal Pharma Srl
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bari, Italy , Chieti, Italy , Desio, Italy , Giulianova, Italy , Lanciano, Italy , Milan, Italy , Ortona, Italy , Sesto San Giovanni, Italy , Sulmona, Italy , Teramo, Italy and 1 more location